Drug intelligence / Profile preview

MCS2105

Development stage: Unknown
Lead developer: Merck KGaA
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

MCS2105 is a small molecule drug candidate developed as an epigenetic modulator, specifically functioning as a selective inhibitor of class I histone deacetylases (HDACs). It is designed to target and inhibit the activity of HDAC enzymes, which play a key role in regulating gene expression by modifying chromatin structure. By inhibiting class I HDACs, MCS2105 aims to induce cell cycle arrest and apoptosis in cancer cells, making it primarily investigated for use in oncology indications such as solid tumors and hematological malignancies. The drug has been evaluated in early-phase clinical trials for its safety and preliminary efficacy.

Targets

HDAC (HDAC family)

Beyond the preview

Go deeper on MCS2105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCS2105.

Explore the full profile